MedPath

MedImmune LLC

MedImmune LLC logo
🇺🇸United States
Ownership
Subsidiary
Established
1987-01-01
Employees
5K
Market Cap
-
Website
http://medimmune.com

Clinical Trials

292

Active:25
Completed:233

Trial Phases

5 Phases

Phase 1:147
Phase 2:81
Phase 3:25
+2 more phases

Drug Approvals

6

CANADA:3

Drug Approvals

RESPIGAM

CANADA

RESPIGAM

CANADA

RESPIGAM

CANADA

Clinical Trials

Distribution across different clinical trial phases (270 trials with phase data)• Click on a phase to view related trials

Phase 1
147 (54.4%)
Phase 2
81 (30.0%)
Phase 3
25 (9.3%)
Phase 4
15 (5.6%)
Not Applicable
1 (0.4%)
phase_2_3
1 (0.4%)

A Phase 1b, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in Combination with Axitinib in Subjects with Advanced Renal Cell Carcinoma

Phase 1
Active, not recruiting
Conditions
Advanced Renal Cell Carcinoma
Interventions
First Posted Date
2020-08-21
Last Posted Date
2025-07-25
Lead Sponsor
AstraZeneca AB
Target Recruit Count
93
Registration Number
2023-509604-15-00
Locations
🇫🇷

Institut Gustave Roussy, Villejuif, France

🇪🇸

Institut Catala D'oncologia, L'hospitalet De Llobregat, Spain

🇪🇸

Hospital Del Mar, Barcelona, Spain

and more 9 locations

IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.

Phase 1
Completed
Conditions
Advanced Solid Tumors
First Posted Date
2020-02-07
Last Posted Date
2022-08-15
Lead Sponsor
MedImmune LLC
Target Recruit Count
57
Registration Number
NCT04261075
Locations
🇨🇭

Research Site, Lausanne, Switzerland

Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC

Phase 2
Withdrawn
Conditions
Microsatellite-stable Colorectal Cancer
Interventions
Drug: Standard of Care - mFOLFOX6
Drug: E1 - mFOLFOX and durvalumab
Drug: E2 - mFOLFOX6, durvalumab and oleclumab
Drug: E3 - mFOLFOX6, durvalumab and monalizumab
First Posted Date
2019-10-30
Last Posted Date
2020-09-21
Lead Sponsor
MedImmune LLC
Registration Number
NCT04145193

A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide

Phase 1
Completed
Conditions
Type 2 Diabetes Mellitus
First Posted Date
2019-09-16
Last Posted Date
2020-04-07
Lead Sponsor
MedImmune LLC
Target Recruit Count
36
Registration Number
NCT04091373
Locations
🇺🇸

Research Site, Daytona Beach, Florida, United States

COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC

Phase 1
Terminated
Conditions
Metastatic Microsatellite-stable Colorectal Cancer
Interventions
First Posted Date
2019-08-28
Last Posted Date
2023-11-15
Lead Sponsor
MedImmune LLC
Target Recruit Count
61
Registration Number
NCT04068610
Locations
🇪🇸

Research Site, Madrid, Spain

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 54
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.